- Home
- NTRB vs CUE Comparison
NTRB vs CUE Comparison
Compare NTRB & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NTRB
- CUE
- Stock Information
- Founded
- NTRB 2016
- CUE 2014
- Country
- NTRB United States
- CUE United States
- Employees
- NTRB N/A
- CUE N/A
- Industry
- NTRB Industrial Specialties
- CUE Biotechnology: Pharmaceutical Preparations
- Sector
- NTRB Health Care
- CUE Health Care
- Exchange
- NTRB Nasdaq
- CUE Nasdaq
- Market Cap
- NTRB 59.1M
- CUE 48.0M
- IPO Year
- NTRB N/A
- CUE 2018
- Fundamental
- Price
- NTRB $9.99
- CUE $0.68
- Analyst Decision
- NTRB Buy
- CUE Strong Buy
- Analyst Count
- NTRB 1
- CUE 3
- Target Price
- NTRB $13.00
- CUE $3.00
- AVG Volume (30 Days)
- NTRB 128.8K
- CUE 313.6K
- Earning Date
- NTRB 09-02-2025
- CUE 08-13-2025
- Dividend Yield
- NTRB N/A
- CUE N/A
- EPS Growth
- NTRB N/A
- CUE N/A
- EPS
- NTRB N/A
- CUE N/A
- Revenue
- NTRB $2,398,437.00
- CUE $7,991,000.00
- Revenue This Year
- NTRB $560.75
- CUE N/A
- Revenue Next Year
- NTRB $588.39
- CUE $23.84
- P/E Ratio
- NTRB N/A
- CUE N/A
- Revenue Growth
- NTRB 18.92
- CUE 13.83
- 52 Week Low
- NTRB $3.72
- CUE $0.45
- 52 Week High
- NTRB $11.78
- CUE $1.99
- Technical
- Relative Strength Index (RSI)
- NTRB 69.95
- CUE 47.91
- Support Level
- NTRB $7.52
- CUE $0.65
- Resistance Level
- NTRB $11.68
- CUE $0.71
- Average True Range (ATR)
- NTRB 0.67
- CUE 0.08
- MACD
- NTRB 0.19
- CUE 0.00
- Stochastic Oscillator
- NTRB 62.19
- CUE 38.62
About NTRB Nutriband Inc.
Nutriband Inc is engaged in the development of a portfolio of transdermal pharmaceutical products. AVERSA technology is the company's product that incorporates aversive agents to prevent the Abuse, Diversion, Misuse, and Accidental exposure of drugs with abuse potential specifically Opioids. The majority of the revenue is generated from the sale of goods that include consumer transdermal and coated products.
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.